CloSys Corp. is seeking $2.4 million from an equity offering, according to documents filed with the Securities & Exchange Commission.

The company, based in New Brighton, Minn., already has raised $1.5 million, according to the filing.

Founded in 2005 by chief scientific officer Karol Nowakowski, CloSys is developing a clotting technology designed to quickly seal an artery wall after vascular surgery. The company expects to release results from a pivotal clinical trial in the U.S. by the end of the year.

CEO Gervaise Wilhelm founded AngioMedics Inc. (now a Boston Scientific Corp. (NYSE:BSX) subsidiary), FiberOptic Medical Systems Inc. (sold to a European private equity group), publicly traded Optical Sensors Inc., and XRT Corp. (sold to Medtronic Inc. (NYSE:MDT). She also is a former COO of Uromedica Inc.